An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)
Conclusion and PerspectivesDAPPER study investigates whether dapagliflozin decreases albuminuria and exerts beneficial effects on the failing heart in T2D patients. (UMIN000025102).
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Failure | Study | Urology & Nephrology